ASCO GU 2025: Some kidney cancer patients can stop combination treatment after two years
A new study presented today by researchers at Fox Chase Cancer Center shows that some…
Browsing: ASCO
ASCO GU 2025: New findings on tumour reduction and survival outcomes in advanced renal cell carcinoma
Thomas E. Hutsonchief of the Haematology Oncology Division at Texas Tech University Health Sciences Centre,…
ASCO GU 2025: Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities
A new study from the UK found that a mobile prostate cancer screening clinic called…
ASCO GU 2025: Talazoparib and enzalutamide combination improves survival in some patients with prostate cancer
Patients with castration-resistant metastatic prostate cancer with or without HRR gene alterations treated with a…
ASCO GU 2025: ENZA-p combination treatment improves survival for metastatic prostate cancer
New research findings were reported today from the ENZA-p study (ANZUP 1901), led by the…
The OJC Episode 7: ASCO Special Episode Part 2
Welcome to Episode 6 of the second series of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson for the first ASCO 2024 Special.
The OJC Episode 6: ASCO Special Episode Part 1
Welcome to Episode 6 of the second series of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson for the first ASCO 2024 Special.
ASCO 2024: Novel CAR T cell therapy obe-cel yields strong remission rates in adults with relapsed or refractory B-ALL
The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell therapy obecabtagene autoleucel (obe-cel) achieved durable remissions…
ASCO 2024: Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer
For patients with locally advanced oesophageal adenocarcinoma that can be treated with surgery, chemotherapy treatment…
ASCO 2024: Trastuzumab deruxtecan significantly improves progression-free survival In breast cancer patients previously treated with endocrine therapy
Trastuzumab deruxtecan delays cancer growth for people with hormone receptor-positive (HR+), human epidermal growth factor…